423 related articles for article (PubMed ID: 10707955)
1. Tamoxifen-bound estrogen receptor (ER) strongly interacts with the nuclear matrix protein HET/SAF-B, a novel inhibitor of ER-mediated transactivation.
Oesterreich S; Zhang Q; Hopp T; Fuqua SA; Michaelis M; Zhao HH; Davie JR; Osborne CK; Lee AV
Mol Endocrinol; 2000 Mar; 14(3):369-81. PubMed ID: 10707955
[TBL] [Abstract][Full Text] [Related]
2. Novel nuclear matrix protein HET binds to and influences activity of the HSP27 promoter in human breast cancer cells.
Oesterreich S; Lee AV; Sullivan TM; Samuel SK; Davie JR; Fuqua SA
J Cell Biochem; 1997 Nov; 67(2):275-86. PubMed ID: 9328833
[TBL] [Abstract][Full Text] [Related]
3. HET/SAF-B overexpression causes growth arrest and multinuclearity and is associated with aneuploidy in human breast cancer.
Townson SM; Sullivan T; Zhang Q; Clark GM; Osborne CK; Lee AV; Oesterreich S
Clin Cancer Res; 2000 Sep; 6(9):3788-96. PubMed ID: 10999774
[TBL] [Abstract][Full Text] [Related]
4. Involvement of G1/S cyclins in estrogen-independent proliferation of estrogen receptor-positive breast cancer cells.
Bindels EM; Lallemand F; Balkenende A; Verwoerd D; Michalides R
Oncogene; 2002 Nov; 21(53):8158-65. PubMed ID: 12444551
[TBL] [Abstract][Full Text] [Related]
5. Scaffold attachment factor SAFB1 suppresses estrogen receptor alpha-mediated transcription in part via interaction with nuclear receptor corepressor.
Jiang S; Meyer R; Kang K; Osborne CK; Wong J; Oesterreich S
Mol Endocrinol; 2006 Feb; 20(2):311-20. PubMed ID: 16195251
[TBL] [Abstract][Full Text] [Related]
6. Both N- and C-terminal transactivation functions of DNA-bound ERalpha are blocked by a novel synthetic estrogen ligand.
Yamamoto Y; Wada O; Takada I; Yogiashi Y; Shibata J; Yanagisawa J; Kitazato K; Kato S
Biochem Biophys Res Commun; 2003 Dec; 312(3):656-62. PubMed ID: 14680815
[TBL] [Abstract][Full Text] [Related]
7. Human estrogen receptor ligand activity inversion mutants: receptors that interpret antiestrogens as estrogens and estrogens as antiestrogens and discriminate among different antiestrogens.
Montano MM; Ekena K; Krueger KD; Keller AL; Katzenellenbogen BS
Mol Endocrinol; 1996 Mar; 10(3):230-42. PubMed ID: 8833652
[TBL] [Abstract][Full Text] [Related]
8. EphA2 overexpression decreases estrogen dependence and tamoxifen sensitivity.
Lu M; Miller KD; Gokmen-Polar Y; Jeng MH; Kinch MS
Cancer Res; 2003 Jun; 63(12):3425-9. PubMed ID: 12810680
[TBL] [Abstract][Full Text] [Related]
9. Various phosphorylation pathways, depending on agonist and antagonist binding to endogenous estrogen receptor alpha (ERalpha), differentially affect ERalpha extractability, proteasome-mediated stability, and transcriptional activity in human breast cancer cells.
Marsaud V; Gougelet A; Maillard S; Renoir JM
Mol Endocrinol; 2003 Oct; 17(10):2013-27. PubMed ID: 12855746
[TBL] [Abstract][Full Text] [Related]
10. mRNA expression of the type I growth factor receptors in the human breast cancer cells MCF-7: regulation by estradiol and tamoxifen.
Revillion F; Pawlowski V; Lhotellier V; Louchez MM; Peyrat JP
Anticancer Res; 2003; 23(2B):1455-60. PubMed ID: 12820409
[TBL] [Abstract][Full Text] [Related]
11. Allosteric silencing of activating function 1 in the 4-hydroxytamoxifen estrogen receptor complex is induced by substituting glycine for aspartate at amino acid 351.
MacGregor Schafer J; Liu H; Bentrem DJ; Zapf JW; Jordan VC
Cancer Res; 2000 Sep; 60(18):5097-105. PubMed ID: 11016635
[TBL] [Abstract][Full Text] [Related]
12. Menin, a product of the MENI gene, binds to estrogen receptor to enhance its activity in breast cancer cells: possibility of a novel predictive factor for tamoxifen resistance.
Imachi H; Murao K; Dobashi H; Bhuyan MM; Cao X; Kontani K; Niki S; Murazawa C; Nakajima H; Kohno N; Yamashita H; Iwase H; Hayashi S; Ishida T; Yamauchi A
Breast Cancer Res Treat; 2010 Jul; 122(2):395-407. PubMed ID: 19847644
[TBL] [Abstract][Full Text] [Related]
13. Antiestrogenic and DNA damaging effects induced by tamoxifen and toremifene metabolites.
Liu X; Pisha E; Tonetti DA; Yao D; Li Y; Yao J; Burdette JE; Bolton JL
Chem Res Toxicol; 2003 Jul; 16(7):832-7. PubMed ID: 12870885
[TBL] [Abstract][Full Text] [Related]
14. A fusion protein of the estrogen receptor (ER) and nuclear receptor corepressor (NCoR) strongly inhibits estrogen-dependent responses in breast cancer cells.
Chien PY; Ito M; Park Y; Tagami T; Gehm BD; Jameson JL
Mol Endocrinol; 1999 Dec; 13(12):2122-36. PubMed ID: 10598586
[TBL] [Abstract][Full Text] [Related]
15. p27(Kip1) induces quiescence and growth factor insensitivity in tamoxifen-treated breast cancer cells.
Carroll JS; Lynch DK; Swarbrick A; Renoir JM; Sarcevic B; Daly RJ; Musgrove EA; Sutherland RL
Cancer Res; 2003 Aug; 63(15):4322-6. PubMed ID: 12907598
[TBL] [Abstract][Full Text] [Related]
16. Expression and regulation of Cyr61 in human breast cancer cell lines.
Tsai MS; Bogart DF; Li P; Mehmi I; Lupu R
Oncogene; 2002 Jan; 21(6):964-73. PubMed ID: 11840342
[TBL] [Abstract][Full Text] [Related]
17. Differential recruitment of coregulator proteins steroid receptor coactivator-1 and silencing mediator for retinoid and thyroid receptors to the estrogen receptor-estrogen response element by beta-estradiol and 4-hydroxytamoxifen in human breast cancer.
Fleming FJ; Hill AD; McDermott EW; O'Higgins NJ; Young LS
J Clin Endocrinol Metab; 2004 Jan; 89(1):375-83. PubMed ID: 14715875
[TBL] [Abstract][Full Text] [Related]
18. Identification of charged residues in an N-terminal portion of the hormone-binding domain of the human estrogen receptor important in transcriptional activity of the receptor.
Pakdel F; Reese JC; Katzenellenbogen BS
Mol Endocrinol; 1993 Nov; 7(11):1408-17. PubMed ID: 8114756
[TBL] [Abstract][Full Text] [Related]
19. Circumventing tamoxifen resistance in breast cancers using antiestrogens that induce unique conformational changes in the estrogen receptor.
Connor CE; Norris JD; Broadwater G; Willson TM; Gottardis MM; Dewhirst MW; McDonnell DP
Cancer Res; 2001 Apr; 61(7):2917-22. PubMed ID: 11306468
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of tumor-associated fatty acid synthase activity antagonizes estradiol- and tamoxifen-induced agonist transactivation of estrogen receptor (ER) in human endometrial adenocarcinoma cells.
Menendez JA; Oza BP; Atlas E; Verma VA; Mehmi I; Lupu R
Oncogene; 2004 Jun; 23(28):4945-58. PubMed ID: 15094777
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
